Compare CVRx, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 234 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.66
-135.56%
5.96
Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2026)
Net Profit:
-14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-65.3%
0%
-65.3%
6 Months
-64.57%
0%
-64.57%
1 Year
-67.27%
0%
-67.27%
2 Years
-72.25%
0%
-72.25%
3 Years
-86.43%
0%
-86.43%
4 Years
-73.1%
0%
-73.1%
5 Years
-88.55%
0%
-88.55%
CVRx, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
56.42%
EBIT Growth (5y)
-219.67%
EBIT to Interest (avg)
-23.39
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.47
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
74.41%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-4.07
EV to EBITDA
-4.13
EV to Capital Employed
15.47
EV to Sales
3.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-380.25%
ROE (Latest)
-135.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 25 Schemes (11.25%)
Foreign Institutions
Held by 35 Foreign Institutions (6.75%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
15.70
13.60
15.44%
Operating Profit (PBDIT) excl Other Income
-12.80
-14.20
9.86%
Interest
1.60
1.50
6.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.00
-14.70
4.76%
Operating Profit Margin (Excl OI)
-829.20%
-1,057.90%
22.87%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 15.44% vs 15.25% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 4.76% vs -5.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
56.70
51.30
10.53%
Operating Profit (PBDIT) excl Other Income
-50.50
-58.90
14.26%
Interest
5.80
4.40
31.82%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-53.30
-60.00
11.17%
Operating Profit Margin (Excl OI)
-904.90%
-1,159.80%
25.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.53% vs 30.53% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.17% vs -45.63% in Dec 2024
About CVRx, Inc. 
CVRx, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






